Press Releases
Muscle tissue is an essential functional component of the body, generating force and movement through cycles of contraction and relaxation — processes fundamental to sustaining life and maintaining postural stability. In vertebrates, muscles are broadly classified into three types: smooth muscle, cardiac muscle, and skeletal muscle. Smooth muscle lines the walls of internal organs, while cardiac muscle is found exclusively in the heart; both contract autonomously without conscious input. Skeletal muscle is the most abundant muscle type and is attached to the skeleton, enabling voluntary movement throughout the body. This article focuses on the application of AAV in skeletal muscle research.

Figure 1.
Classification of muscle types in vertebrates (Source: Wikipedia)
Skeletal muscle is composed of bundles of muscle fibers, each containing myofibrils made up of myofilaments. The fibers are rich in sarcoplasmic reticulum and mitochondria, which coordinate contraction and energy supply. Commonly studied skeletal muscles include the gastrocnemius, tibialis anterior, soleus, biceps femoris, and quadriceps.

Figure 2. Structural organization of skeletal muscle (PMID: 35631979)

Figure 3. Hind limb skeletal muscle anatomy in mice (PMID: 34867435)
Skeletal muscle diseases are diverse in etiology and profoundly impair patients' quality of life. Muscular dystrophies (MD) are a group of inherited disorders characterized by progressive muscle wasting and weakness. The most common and severe form is Duchenne muscular dystrophy (DMD), an X-linked recessive condition that primarily affects males. Symptoms of muscle weakness typically emerge around age 4 and progress rapidly, leading to impaired mobility, eventual dependence on ventilatory support, and premature death. Other active areas of skeletal muscle research include inflammatory myopathies, metabolic myopathies, and mechanisms of muscle regeneration.

Figure 4.
Histological comparison of healthy versus DMD muscle tissue (PMID: 33602943)
Viral vectors are routinely
used in muscle research to deliver genetic material and modulate gene
expression in host cells. Recombinant adeno-associated viral vectors (rAAV)
are the most widely adopted platform for in vivo gene delivery, offering a
broad range of serotypes, low immunogenicity, stable long-term transgene
expression, and a wide host range. These properties have made rAAV an
invaluable tool in muscle biology research.
A comparative study evaluating AAV serotypes 1–10 in murine skeletal muscle found that AAV9 and AAV8 achieve the highest transduction efficiency. Additionally, systemic delivery of the myoAAV1A serotype via intravenous injection has been shown to preferentially transduce striated muscle — encompassing both skeletal muscle and cardiac muscle.

Figure 5.
Striated muscle targeting following intravenous delivery of myoAAV1A in mice
(PMID: 34506722)
Achieving muscle-specific
transgene expression requires not only a muscle-tropic AAV serotype, but also
an appropriate cell-type-specific promoter. The dMCK/tMCK and ACTA1
promoters drive expression selectively in skeletal muscle, while the MHCK7
promoter directs expression across striated muscle (both skeletal and cardiac).
Considerable research attention has also focused on myoblasts — muscle
progenitor cells that proliferate via mitosis and play a pivotal role in muscle
growth and repair. Myoblast-specific transduction can be achieved using the Myog
promoter.
Recommended AAV Serotypes and Promoters for
Muscle Targeting
|
AAV
Serotypes |
Promoters |
|
|
AAV9 / AAV8 |
dMCK, tMCK,
ACTA1 |
Skeletal
muscle |
|
MHCK7 |
Striated
muscle |
|
|
Myog |
Myoblasts |
|
|
SM22a /
EnSM22a |
Smooth
muscle |
|
|
myoAAV1A |
CBh / CMV /
CAG / U6 |
Broad
infection |
Table 1.
Recommended AAV serotypes and promoters for muscle-targeted gene delivery
The two most commonly used
delivery methods for AAV-mediated muscle gene transfer are intramuscular injection
and tail vein injection. Specific injection parameters are summarized in
the table below.
AAV Delivery Methods for Muscle-Targeted Gene
Transfer
|
Injection
Route |
Pros |
Cons |
AAV
Dosage |
|
Intramuscular
injection |
• High
transduction efficiency •
Strong targeting capability |
•
Invasive, causing tissue damage •
Uneven expression, high expression only around the injection site |
~1E+11 vg /side 25 μL /side |
|
Tail vein
injection |
•
Simple operation • Non-invasive
(to the muscle) |
• Poor
targeting capability • Low
transduction efficiency |
~5E+11vg /mouse 100-200 μL |
Table 2.
Injection routes and dosing guidelines for AAV-mediated muscle gene delivery in
adult mice
Sarcopenia is a progressive neuromuscular disorder characterized by age-related muscle atrophy and weakness, yet its molecular mechanisms remain incompletely understood. The study observed that Agrin protein levels in murine skeletal muscle decline with age. Using AAV vectors supplied by OBiO Tech, the researchers delivered a miniaturized Agrin construct to skeletal muscle via overexpression, demonstrating that elevated Agrin levels enhance muscle performance in aged mice. The improvement in muscle function was mediated through activation of Yap signaling and upregulation of dystrophin expression. These findings provide a mechanistic rationale for targeting the Agrin pathway in the treatment of sarcopenia.

Figure 6.
Agrin overexpression reverses age-related muscle weakness (PMID: 38461287)
|
Parameter |
Details |
|
Viral
vector |
AAV9-CB-mini-Agrin |
|
Animal
model |
mice |
|
Injection
route |
Intramuscular
injection |
|
Target
tissue |
Gastrocnemius,
tibialis anterior muscle |
|
Dosage |
2E+12
vg/mL – 1E +13 vg/mL ,30-50μL |
|
Detection
time |
5
weeks |
A study published in Cell
Metabolism describes the development of FiLa — a highly sensitive,
fast-responding lactate biosensor capable of detecting subtle lactate
fluctuations in living cells and intact animals. The researchers used AAV to
introduce the FiLa sensor into murine skeletal muscle, enabling direct
visualization of elevated lactate levels in diabetic mice. This technology
offers a promising platform for simple and efficient lactate monitoring with
potential applications in clinical screening. The AAV constructs used in this
study were also produced by OBiO Tech.

Figure 7.
The lactate biosensor FiLa shows robust expression in murine skeletal muscle
(PMID: 36309010)
|
Parameter |
Details |
|
Viral
construct |
AAV9-CMV-FiLa,
AAV9-CMV-FiLa-C |
|
Animal
model |
C57
mice, db/db mice |
|
Injection
route |
Intramuscular
injection |
|
Target
tissue |
Gastrocnemius
muscle |
|
Dosage |
6E
+10 vg, 50 μL |
|
Detection
time |
4-6
weeks |
[3]
Duan D, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.